Small molecule lipid (SURYA-101) as a potential drug to prevent and manage diabetic retinopathy (DR)

---

Authors

Undurti Das¹

1. UND Life Sciences

Conference / event

10th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), February 2017 (Paris, France)

Poster summary

Diabetic retinopathy (DR) is a common cause of significant vision loss and blindness in those with diabetes mellitus. Yet, there is no effective therapeutic intervention available for its prevention and management. SURYA-101, a lipid based small molecule-lipoxin A4 (LXA4) that has potent anti-inflammatory and immunomodulatory actions is being developed as a potential drug for DR. It also has the potential to treat AMD (age-related macular degeneration) and retinopathy of prematurity.

Keywords

Lipoxin A4, Diabetic retinopathy, Inflammation

Research areas

Medicine, Immunology, Biochemistry, Molecular and Cellular Biosciences, Biological Sciences

References

1. Kaviarasan K, Mohanlal J, Mohammad Mulla MA, Shanmugam S, Sharma T, Das UN, Angayarkanni N. Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance as potential risk factors for diabetic retinopathy. Metabolism 2015; 64: 958-966.
2. Shen J, Bi Y-L, Das UN. Potential role of polyunsaturated fatty acids in diabetic retinopathy. Arch Med Sci 2014; 10: 1167-1174.
3. Dalan D, Nandini P, Angayarkanni N, Kaviarasan K, Thanikachalam S, Das UN, Ratra D. Interchangeability of retinal perfusion indices in different-sized angiocubes: An optical coherence tomography angiography study in diabetic retinopathy. Indian J Ophthalmol. 2020 Mar;68(3):484-489.

Funding

No data provided

Supplemental files

No data provided

Additional information

Competing interests

WE are planning to develop SURYA-101 as a potential drug for Diabetic retinopathy

Data availability statement

The datasets generated during and / or analyzed during the current study are available from the corresponding author on reasonable request.

Creative Commons license

Copyright © 2023 Das. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.